Chemoembolization and bland embolization: a critical appraisal.

Area of Science:

• Hepatobiliary oncology
• Interventional radiology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
• Many HCC patients are ineligible for curative treatments.
• Palliative options are crucial for managing advanced HCC.

Purpose of the Study:

• To evaluate the efficacy of bland and chemoembolization as palliative treatments for hepatocellular carcinoma (HCC).
• To assess the role of embolization therapies in the management of HCC patients.

Main Methods:

• Review of controlled trials evaluating bland embolization.
• Review of controlled trials evaluating chemoembolization.
• Analysis of embolization as primary treatment for HCC.

Main Results:

• Embolization therapies, particularly chemoembolization, demonstrate effectiveness in prolonging survival for selected HCC patients.
• Bland embolization may also offer survival benefits as a primary treatment.
• The use of these therapies before resection, transplantation, or with ablative methods remains controversial.

Conclusions:

• Transarterial embolization is an effective palliative strategy for select hepatocellular carcinoma patients.
• Further research is needed to clarify the role of embolization in multimodal HCC treatment strategies.